Comparison of wild-type (WT) and Gα₁₃binding–deficient mutant β₃in agonist and shear-dependent MV release and PS exposure. (A) MV release from 3000 s⁻¹ of shear/0.05 U/mL of thrombin-stimulated β₃^−/− platelets expressing WT or AAA⁷³³-mutant β₃ (Gα₁₃ binding deficient) transplanted using bone marrow stem-cell transplantation technique. (B) PS exposure on platelets expressing WT or AAA⁷³³-mutant β₃ treated with thrombin and shear. (C) MV release from platelets expressing WT or AAA⁷³³-mutant β₃ treated with CRP (1 µg/mL) and shear. (D) PS exposure on platelets expressing WT or AAA⁷³³-mutant β₃ treated with CRP and shear. Data are presented as mean ± standard error of the mean (n = 4). ****P < .0001.